Losartan Potassium Tablet, Film Coated
Product Images NDC 71205-226

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 71205-226). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-226-30 (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 06)

This is a description of Losartan Potassium medication manufactured by Zhejang Huahai Pharmaceutical Co.Ltd. The medication is a prescription-only type and is packaged in a white-to-off-white film-coated tablet form. Each tablet contains 25mg of Losartan Potassium, USP ot PR. The lot number is EW000000 and the product ID is SL022690. It is recommended to store the medication at 20°C-25°C (68°F-77°F). It is important to keep the medication out of reach of children.*

FDA Label Image

Chemical Structure (Spl Image1 Structure1)

FDA Label Image

Figure 1 (Spl Image2 Figure1)

This appears to be a comparison of two medications, Atenolol and Losartan Potassium. It shows a percentage of patients with a primary endpoint and an adjusted risk reduction of 13% with a p-value of 0.021. The graph shows study data for a period of 66 months.*

FDA Label Image

Figure 2 (Spl Image3 Figure2)

This text appears to compare the medication Atenolol with Losartan Potassium in terms of adjusted risk reduction, where Losartan Potassium has shown a 25% risk reduction compared to Atenolol. The percentage of patients with fatal/non-fatal stroke over a period of 66 months has also been recorded. No further information is available to provide a context for this data.*

FDA Label Image

Figure 3 (Spl Image4 Figure3)

This is a table presenting the primary endpoint events for different demographic subgroups in clinical trials comparing the efficacy of Losartan Potassium and Atenolol. The primary composite endpoint is stroke (fatal/non-fatal). The subgroups are defined by age, gender, race, ISH, diabetes, and history of CVD. The table includes the number of events, event rate, and hazard ratio (95% CI) for each subgroup. The symbols in the table are proportional to the sample size. The text also mentions that the results were adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy.*

FDA Label Image

Figure 4 (Spl Image5 Figure4)

This seems to be a chart showing the percentage of patients with an event over a 48 month period. The chart compares the outcomes of patients taking Losartan Potassium versus Placebo. It appears that there was a risk reduction of 16.1% in the Losartan group compared to Placebo. The p-value is reported as 0.022.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.